FindTrial
Sign In

Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

Post-Trial Access for Guselkumab in Patients With Familial Adenomatous Polyposis Who Are Experiencing Clinical Benefit After Completing 48 Weeks of Treatment in CNTO1959COR1001

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04948398
Enrollment
Unknown
Registered
2021-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomatous Polyposis Coli

Brief summary

The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.

Interventions

DRUGGuselkumab

Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.

Sponsors

Janssen Research & Development, LLC
Lead SponsorINDUSTRY

Eligibility

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026